The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.
PCS IX
NCT02685397
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
Phase III |
Josie Pepe
514-934-1934 poste 48186
|
A retrospective observational study to
assess imaging and management of
patients with castration-resistant
prostate cancer
AMGEN 20150126
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Autres |
Maria Simona Grigorie
514-934-1934 poste 35160
|
TALAPRO-3: a phase 3, randomized, double-blind, study of talazoparib with enzalutamide versus placebo with enzalutamide in men with ddr gene mutated metastatic castration-sensitive prostate cancer
TALAPRO-3
NCT04821622
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Rodrigo Skowronski
514-934-1934 poste 36275
|
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer
PATRON
NCT04557501
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Rodrigo Skowronski
514-934-1934 poste 36275
|
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
PSMAddition
NCT04720157
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Rodrigo Skowronski
514-934-1934 poste 36275
|
Detection and Monitoring of Metastasis by 18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer and Negative Conventional Imaging
PROSTEP-002
NCT04655365
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Rodrigo Skowronski
514-934-1934 poste 36275
|
Detection and Monitoring of Metastasis by 18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer and Negative Conventional Imaging
PROSTEP-002
NCT04655365
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
|
Marilyn Savard
418-525-4444 poste 20414
|
An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of AZD5305 Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer
ASCERTAIN
NCT05938270
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Marilyn Savard
418-525-4444 poste 67703
|
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
EORTC-1333-GUCG / PEACE III
NCT02194842
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Phase III |
Pascale Lévesque-Bernier
418-525-4444 poste 16860
|
A Randomized Phase II Trial Evaluating Hight Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
PR.19
NCT02960087
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Phase II |
Josée Allard
418-525-4444 poste 16730
|
Groupe d'étude en oncologie du Québec